We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.
- Authors
Pencina, Karol Mateusz; Valderrabano, Rodrigo; Wipper, Benjamin; Orkaby, Ariela R.; Reid, Kieran F.; Storer, Thomas; Lin, Alexander P.; Merugumala, Sai; Wilson, Lauren; Latham, Nancy; Ghattas-Puylara, Catherine; Ozimek, Noelle E.; Ming Cheng; Bhargava, Avantika; Memish-Beleva, Yusnie; Lawney, Brian; Lavu, Siva; Swain, Pamela M.; Apte, Rajendra S.; Sinclair, David A.
- Abstract
Context: Nicotinamide adenine dinucleotide (NAD) levels decline with aging and age-related decline in NAD has been postulated to contribute to age-related diseases. Objective: We evaluated the safety and physiologic effects of NAD augmentation by administering its precursor, β-nicotinamide mononucleotide (MIB-626, Metro International Biotech, Worcester, MA), in adults at risk for age-related conditions. Methods: Thirty overweight or obese adults, ≥45 years, were randomized in a 2:1 ratio to 2 MIB-626 tablets each containing 500 mg of microcrystalline β-nicotinamide mononucleotide or placebo twice daily for 28 days. Study outcomes included safety; NAD and its metabolome; body weight; liver, muscle, and intra-abdominal fat; insulin sensitivity; blood pressure; lipids; physical performance, and muscle bioenergetics. Results: Adverse events were similar between groups. MIB-626 treatment substantially increased circulating concentrations of NAD and its metabolites. Body weight (difference −1.9 [−3.3, −0.5] kg, P=.008); diastolic blood pressure (difference −7.01 [−13.44, −0.59] mmHg, P=.034); total cholesterol (difference −26.89 [−44.34, −9.44] mg/dL, P=.004), low-density lipoprotein (LDL) cholesterol (−18.73 [−31.85, −5.60] mg/dL, P=.007), and nonhigh-density lipoprotein cholesterol decreased significantly more in the MIB-626 group than placebo. Changes in muscle strength, muscle fatigability, aerobic capacity, and stair-climbing power did not differ significantly between groups. Insulin sensitivity and hepatic and intra-abdominal fat did not change in either group. Conclusions: MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.
- Subjects
NAD (Coenzyme); OBESITY; BLOOD pressure
- Publication
Journal of Clinical Endocrinology & Metabolism, 2023, Vol 108, Issue 8, p1968
- ISSN
0021-972X
- Publication type
Article
- DOI
10.1210/clinem/dgad027